Novel Breakthroughs in Sepsis and Septic Shock Management

Dear Colleagues,

Sepsis and septic shock remain major contributors to morbidity and mortality in critically ill patients worldwide. Despite advances in supportive care, managing these complex conditions continues to pose significant clinical challenges. In light of this, we are pleased to announce the upcoming Special Issue, entitled “Novel Breakthroughs in Sepsis and Septic Shock Management,” which seeks to gather state-of-the-art research and insightful reviews on the latest therapeutic strategies, adjunctive therapies, and monitoring tools that have the potential to transform current clinical practice.

Building on our initial focus on non-amine-based therapies, this expanded Special Issue will now encompass a broader spectrum of innovative interventions and approaches. We invite submissions addressing, but not limited to, the following themes:

Decatecholaminisation and Non-Amine-Based Therapies—investigations into novel vasopressors or vasopressor-sparing treatments (e.g., angiotensin II, vasopressin, and methylene blue) that target vasoplegia and endothelial dysfunction with the potential to minimize catecholamine-related adverse effects.
Beta Blockers and Other Cardiac Modulators—emerging evidence on beta blockers (e.g., esmolol and landiolol) in reducing adrenergic stress and improving hemodynamic stability in septic shock, as well as insights into agents like levosimendan in septic cardiomyopathy management.
Endocrine and Metabolic Support—the role of hydrocortisone, levothyroxine, and other hormone replacement therapies to optimize immune, metabolic, and cardiovascular function in critically ill septic patients.
Immunomodulatory Interventions—exploration of innovative techniques, including biologics, immunoadjuvants, or cytokine adsorption/filtration, aimed at controlling dysregulated immune responses in severe sepsis.
Precision Medicine Approaches—studies on biomarker-driven, gene-based, or phenotype-specific therapies to tailor treatments and improve outcomes at the individual patient level.
Advanced Monitoring and Supportive Technologies—novel methods in hemodynamic or organ function monitoring (e.g., electrical impedance tomography), coupled with targeted interventions such as extracorporeal organ support, that refine patient management and optimize clinical decision-making.
Combined Pharmacological and Non-Pharmacological Strategies—holistic treatment frameworks that integrate multiple therapies, including fluid management, antimicrobial stewardship, and organ-support devices, for synergistic improvements in survival and quality of life.
By assembling cutting-edge research and comprehensive reviews, we aim to provide a robust resource for clinicians, researchers, and students who are dedicated to improving care for patients with sepsis and septic shock. We welcome contributions from diverse fields—such as anesthesiology, critical care, emergency medicine, pharmacology, and immunology—that can help shape a transformative, multi-disciplinary understanding of septic shock management.

We look forward to your submissions, which will help define future directions in this critical area of patient care.

Dr. Iacopo Cappellini
Dr. Vittorio Pavoni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• decatecholaminisation
• non-amine-based therapy
• beta blockers
• hormone replacement
• levosimendan
• Angiotensin II
• sepsis
• septic shock
• septic cardiomyopathy